Other Species / Isoforms
  DUSP6 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K68-ub
IMLRRLQkGNLPVRA
0 2
DUSP6 (human) IMLRRLQkGNLPVRA K68-ub
DUSP6 (mouse) IMLRRLQKGNLPVRA K68
DUSP6 (rat) IMLRRLQKGNLPVRA K68
S159-p
DGSCSSSsPPLPVLG
Upstream
Downstream
4 0
Effects on Modified Protein
  • protein degradation
Kinase, in vitro:
  • ERK2 (human)
Putative in vivo kinases:
  • ERK1 (human)
  • ERK2 (human)
Treatment
  • 4-HT
  • anisomycin
  • cycloheximide
  • PD184352
  • SB202190
  • serum
  • U0126
DUSP6 (human) DGSCSSSsPPLPVLG S159-p
DUSP6 (mouse) DGSCSSSsPPLPVLG S159-p
DUSP6 (rat) DGSCSSSSPPLPVLG S159
S174-p
LGGLRISsDSSsDIE
Upstream
Downstream
1 0
Effects on Modified Protein
  • protein degradation
Putative in vivo kinases:
  • ERK1 (human)
Regulatory protein:
  • PDGFRA (human)
  • PDGFRB (human)
Treatment
  • PDGF
  • U0126
DUSP6 (human) LGGLRISsDSSsDIE S174-p
DUSP6 (mouse) LGGLRISSDSSSDIE S174
DUSP6 (rat) LGGLRISSDSSSDIE S174
S178-p
RISsDSSsDIEsDLD
0 1
DUSP6 (human) RISsDSSsDIEsDLD S178-p
DUSP6 (mouse) RISSDSSSDIESDLD S178
DUSP6 (rat) RISSDSSSDIESDLD S178
S182-p
DSSsDIEsDLDRDPN
0 1
DUSP6 (human) DSSsDIEsDLDRDPN S182-p
DUSP6 (mouse) DSSSDIESDLDRDPN S182
DUSP6 (rat) DSSSDIESDLDRDPN S182
S197-p
SATDSDGsPLSNSQP
Upstream
Downstream
5 0
Effects on Modified Protein
  • protein degradation
Kinase, in vitro:
  • ERK2 (human)
Putative in vivo kinases:
  • ERK1 (human)
  • ERK2 (human)
Treatment
  • 4-HT
  • anisomycin
  • cycloheximide
  • PD184352
  • SB202190
  • serum
  • U0126
DUSP6 (human) SATDSDGsPLSNSQP S197-p
DUSP6 (mouse) SATDSDGsPLSNSQP S197-p
DUSP6 (rat) SATDSDGsPLSNSQP S197-p
K254-ub
FENAGEFkyKQIPIS
0 5
DUSP6 (human) FENAGEFkyKQIPIS K254-ub
DUSP6 (mouse) FENAGEFKYKQIPIS K254
DUSP6 (rat) FENAGEFKYKQIPIS K254
Y255-p
ENAGEFkyKQIPISD
0 1
DUSP6 (human) ENAGEFkyKQIPISD Y255-p
DUSP6 (mouse) ENAGEFKYKQIPISD Y255
DUSP6 (rat) ENAGEFKYKQIPISD Y255
S300-p
CLAGISRsVTVTVAY
Upstream
1 0
Putative in vivo kinases:
  • ERK1 (human)
Regulatory protein:
  • PDGFRA (human)
  • PDGFRB (human)
Treatment
  • PDGF
  • U0126
DUSP6 (human) CLAGISRsVTVTVAY S300-p
DUSP6 (mouse) CLAGISRSVTVTVAY S300
DUSP6 (rat) CLAGISRSVTVTVAY S300
K324-ub
NDAYDIVkMKKsNIs
0 2
DUSP6 (human) NDAYDIVkMKKsNIs K324-ub
DUSP6 (mouse) NDAYDIVKMKKsNIs K324
DUSP6 (rat) NDAYDIVKMKKSNIs K324
S328-p
DIVkMKKsNIsPNFN
Upstream
0 7
Treatment
  • EGF
  • metastatic potential
DUSP6 (human) DIVkMKKsNIsPNFN S328-p
DUSP6 (mouse) DIVKMKKsNIsPNFN S328-p
DUSP6 (rat) DIVKMKKSNIsPNFN S328
S331-p
kMKKsNIsPNFNFMG
Upstream
0 20
Treatment
  • metastatic potential
DUSP6 (human) kMKKsNIsPNFNFMG S331-p
DUSP6 (mouse) KMKKsNIsPNFNFMG S331-p
DUSP6 (rat) KMKKSNIsPNFNFMG S331-p
S351-p
ERTLGLSsPCDNRVP
Upstream
0 3
Treatment
  • selumetinib
  • vemurafenib
DUSP6 (human) ERTLGLSsPCDNRVP S351-p
DUSP6 (mouse) ERTLGLSSPCDNRVP S351
DUSP6 (rat) ERTLGLSSPCDNRVP S351